Details of the SBP

General Information of Synthetic Binding Protein (SBP) (ID: SBP000059)
SBP Name
Anticalin Angiocal
Synonyms
PRS050; PRS-050-PEG40
Design Method Traditional methods (Site-directed mutagenesis and/or Directed evolution)
Highest Status Phase I
Protein Scaffold Information of This SBP
Scaffold ID PS011
Scaffold Info
[1] , [2] , [3]
Scaffold Name Anticalin
Scaffold Class Non-Antibody
Fold Type One Alpha-Helix + Beta-Sheets + Loops
Binding Target(s) of This SBP (BTS)
BTS Name Details Mechanism Application Affinity Research Organization Ref
Vascular endothelial growth factor A
BTS Info
Inhibitor Solid tumour/cancer [ICD-11: 2A00-2F9Z] Kd: 0.025 nM Pieris AG [1] , [2] , [3]
Clinical Trial Information of This SBP
DRKS00003662 Click to show the Detail
Indication Solid Tumor
Phase Phase I
Title A Phase I, Open-label Study of the Safety, Tolerability, and Pharmacokinetics of Angiocal? (PRS-050-PEG40) in Patients With Solid Tumors
Status Completed
Sponsor Pieris AG
NCT01141257 Click to show the Detail
Indication Solid Tumor
Phase Phase I
Title A Phase I, Open-label Study of the Safety, Tolerability, and Pharmacokinetics of?Angiocal??(PRS-050-PEG40) in Patients With Solid Tumors
Status Completed
Sponsor Pieris Pharmaceuticals GmbH
References
1 In vitro-engineered non-antibody protein therapeutics. Protein Cell. 2018 Jan;9(1):3-14.
2 Recent advances in the development of novel protein scaffolds based therapeutics. Int J Biol Macromol. 2017 Sep;102:630-641.
3 Functional characterization of a VEGF-A-targeting Anticalin, prototype of a novel therapeutic human protein class. Angiogenesis. 2016 Jan;19(1):79-94.